# Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

> **NCT00453999** · PHASE2 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 137 (actual)

## Conditions studied

- Influenza

## Interventions

- **DRUG:** Peramivir 200 mg
- **DRUG:** Peramivir 400 mg
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT00453999
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-09
- **Final completion:** 2009-08
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2015-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00453999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00453999, "Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00453999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*